We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The plaintiffs alleged the insulin manufacturers illegally raised the prices of their products to provide rebates for pharmacy benefit managers. Read More
Pharmacy benefit managers in Kentucky pocketed $123.5 million in 2018 due to the practice of “spread pricing,” according to a report from the state Cabinet for Health and Family Services. Read More
Takeda and Lundbeck have requested that the FDA require all applicants for generics of their antidepressant, Trintellix (vortioxetine), to include information on the med’s association with sexual dysfunction. Read More
German regulators are urging clinical trial sponsors in the UK to designate new, European-based representatives as Brexit’s March 29 deadline draws near. Read More
A bill introduced in the California legislature and endorsed by the state’s attorney general would ban controversial “pay-for-delay” deals between branded and generic drugmakers. Read More